ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
67.026,54
2,74%
Brent Oil
83,76
0,67%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Dyne Therapeutics Inc (DYN)

  7. Dyne Therapeutics Inc (DYN) Notícias

DYN

Dyne Therapeutics (DYN)

Dyne Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DYN
DataHoraFonteTítuloCódigoCompanhia
16/05/202417:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
02/05/202417:10GlobeNewswire Inc.Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
27/03/202417:05GlobeNewswire Inc.Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerNASDAQ:DYNDyne Therapeutics Inc
27/03/202409:30GlobeNewswire Inc.Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:DYNDyne Therapeutics Inc
25/03/202408:30GlobeNewswire Inc.Dyne Therapeutics Announces CEO TransitionNASDAQ:DYNDyne Therapeutics Inc
13/03/202408:30GlobeNewswire Inc.Dyne Therapeutics to Present at Stifel 2024 Virtual CNS DaysNASDAQ:DYNDyne Therapeutics Inc
05/03/202410:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:DYNDyne Therapeutics Inc
05/03/202409:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
05/03/202409:40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DYNDyne Therapeutics Inc
05/03/202409:35Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DYNDyne Therapeutics Inc
05/03/202409:30GlobeNewswire Inc.Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
01/03/202423:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
14/02/202418:15GlobeNewswire Inc.Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific ConferenceNASDAQ:DYNDyne Therapeutics Inc
14/02/202410:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DYNDyne Therapeutics Inc
01/02/202409:30GlobeNewswire Inc.Dyne Therapeutics to Present at February Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
19/01/202418:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:DYNDyne Therapeutics Inc
11/01/202418:05GlobeNewswire Inc.Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:DYNDyne Therapeutics Inc
05/01/202418:07Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
05/01/202409:30GlobeNewswire Inc.Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
05/01/202400:46GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
04/01/202423:19Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:DYNDyne Therapeutics Inc
03/01/202418:25GlobeNewswire Inc.Dyne Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
03/01/202408:30GlobeNewswire Inc.Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle DiseasesNASDAQ:DYNDyne Therapeutics Inc
02/01/202418:05GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER TrialsNASDAQ:DYNDyne Therapeutics Inc
07/11/202309:30GlobeNewswire Inc.Dyne Therapeutics to Present at November Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
30/10/202308:30GlobeNewswire Inc.Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical MilestonesNASDAQ:DYNDyne Therapeutics Inc
30/10/202308:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DYNDyne Therapeutics Inc
28/09/202308:30GlobeNewswire Inc.Dyne Therapeutics to Present at October Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
20/09/202317:51Dow Jones NewsDyne Therapeutics Gets New FDA Orphan Drug DesignationNASDAQ:DYNDyne Therapeutics Inc
20/09/202317:05GlobeNewswire Inc.Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:DYNDyne Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:DYN

Seu Histórico Recente

NASDAQ
EFHTU
EF Hutton Acquisition Co...
BIT
UC7F74
Unicredit Bank
USOTC
EVBC
Evolution Blockchain (CE)
BITV
LRCEUR
LoopringCoin V2
BIT
UC72PE
Unicredit Bank
NASDAQ
FKLWQX
HighYield Income ClosedE...
BIT
F15839
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados